Toll Free: 1-888-928-9744

La Jolla Pharmaceutical Company - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

La Jolla Pharmaceutical Company - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'La Jolla Pharmaceutical Company - Product Pipeline Review - 2014', provides an overview of the La Jolla Pharmaceutical Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of La Jolla Pharmaceutical Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of La Jolla Pharmaceutical Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of La Jolla Pharmaceutical Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the La Jolla Pharmaceutical Company's pipeline products

Reasons to buy

- Evaluate La Jolla Pharmaceutical Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of La Jolla Pharmaceutical Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the La Jolla Pharmaceutical Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of La Jolla Pharmaceutical Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of La Jolla Pharmaceutical Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of La Jolla Pharmaceutical Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
La Jolla Pharmaceutical Company Snapshot 5
La Jolla Pharmaceutical Company Overview 5
Key Information 5
Key Facts 5
La Jolla Pharmaceutical Company - Research and Development Overview 6
Key Therapeutic Areas 6
La Jolla Pharmaceutical Company - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
La Jolla Pharmaceutical Company - Pipeline Products Glance 13
La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
La Jolla Pharmaceutical Company - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
La Jolla Pharmaceutical Company - Drug Profiles 17
GCS-100 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LJPC-501 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LJPC-0712 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LJPC-1010 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
LJPC-401 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
LJPC-6417 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
LJPC-101 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
LJPC-201 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
LJPC-301 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
La Jolla Pharmaceutical Company - Pipeline Analysis 27
La Jolla Pharmaceutical Company - Pipeline Products by Target 27
La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration 28
La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type 29
La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action 30
La Jolla Pharmaceutical Company - Recent Pipeline Updates 31
La Jolla Pharmaceutical Company - Dormant Projects 36
La Jolla Pharmaceutical Company - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
abetimus sodium 37
GM-1485 37
La Jolla Pharmaceutical Company - Company Statement 38
La Jolla Pharmaceutical Company - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 4
List of Tables
La Jolla Pharmaceutical Company, Key Information 5
La Jolla Pharmaceutical Company, Key Facts 5
La Jolla Pharmaceutical Company - Pipeline by Indication, 2014 8
La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2014 9
La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2014 10
La Jolla Pharmaceutical Company - Partnered Products in Pipeline, 2014 11
La Jolla Pharmaceutical Company - Partnered Products/ Combination Treatment Modalities, 2014 12
La Jolla Pharmaceutical Company - Phase II, 2014 13
La Jolla Pharmaceutical Company - Phase I, 2014 14
La Jolla Pharmaceutical Company - Preclinical, 2014 15
La Jolla Pharmaceutical Company - Discovery, 2014 16
La Jolla Pharmaceutical Company - Pipeline by Target, 2014 27
La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2014 28
La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2014 29
La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2014 30
La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2014 31
La Jolla Pharmaceutical Company - Dormant Developmental Projects,2014 36
La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2014 37
La Jolla Pharmaceutical Company, Subsidiaries 41 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify